Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : CEO promises to speed data integrity disclosures

share with twitter share with LinkedIn share with facebook
share via e-mail
09/09/2019 | 09:41am EDT
FILE PHOTO: CEO Vas Narasimhan of Swiss drugmaker Novartis addresses the company's annual news conference in Basel

ZURICH (Reuters) - Novartis Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity.

Novartis has said it knew of discrepancies in Zolgensma data it had submitted to the U.S. Food and Drug Administration before it won approval for the world's most expensive medicine in May, but delayed informing regulators until June 28 while it completed an internal investigation.

While the FDA has concluded Zolgensma is safe and effective and should remain on the market, the U.S. drug watchdog raised questions about the timing of Novartis's disclosure. U.S. senators have also demanded the Swiss drugmaker explain why it took so long to inform the agency.

Novartis could face possible civil or criminal penalties, the FDA has said. Zolgensma treats spinal muscular atrophy, the leading genetic cause of death in infants.

"We are making a voluntary commitment to notify the FDA within five business days of receipt by our quality (control) organization of any credible allegation related to data integrity impacting any pending application in the Novartis Group," Narasimhan said at an investor event, adding Novartis will take a similar approach in other jurisdictions.

Novartis said it gave "detailed explanations" on Aug. 23 to the FDA about the company's investigation into the data manipulation, and addressed regulators' questions over why the company waited until late June to make disclosures.

The company has said it has "exited" scientists it identified in its data manipulation probe. One of those scientists, Brian Kaspar, through his lawyer, has denied wrongdoing.

During Monday's investor event on corporate governance, Narasimhan said the Basel-based company has countless instances where its employees must use judgment about how to manage potential problems that crop up with its drugs, but that the tumult surrounding Zolgensma prompted it to change its practices.

"What we realized through this situation is, during a filing, it's difficult for us to exercise that judgment without it being later considered maybe not the best judgment," Narasimhan said. "So we're just taking judgment out of that equation" with the new five-day rule.

(Reporting by John Miller; Editing by Michael Shields)

By John Miller

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
09/20DR REDDY LABORATORIES : . Reddy's Suspends Shipments of Ranitidine
09/20NOVARTIS : AveXis presents new data at EPNS continuing to show significant thera..
09/18NOVARTIS : Sandoz Halting Ranitidine Distribution
09/18NOVARTIS : halts distribution of its Zantac versions amid probe into impurities
09/18NOVARTIS : Cosentyx positive 16-week PREVENT results advance potential new indic..
09/17NOVARTIS : Initiation of Novartis Entresto in-hospital included in the new ACC E..
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) -2-
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) Positive 16-week Prevent Results A..
09/16NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
09/14NOVARTIS : Trial and Error -2-
More news
Financials (USD)
Sales 2019 47 003 M
EBIT 2019 13 855 M
Net income 2019 10 274 M
Debt 2019 17 463 M
Yield 2019 3,41%
P/E ratio 2019 18,8x
P/E ratio 2020 20,5x
EV / Sales2019 4,61x
EV / Sales2020 4,25x
Capitalization 199 B
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,55  $
Last Close Price 86,98  $
Spread / Highest target 23,6%
Spread / Average Target 8,71%
Spread / Lowest Target -6,27%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS15.60%199 009
JOHNSON & JOHNSON0.82%347 446
ROCHE HOLDING LTD.16.27%245 289
MERCK AND COMPANY11.45%218 042
PFIZER-15.95%202 934
NOVO NORDISK AS17.30%124 981